Back to Search
Start Over
The Efficacy and Safety of Once-daily Fluticasone Furoate/Umeclidinium/Vilanterol Versus Twice-daily Budesonide/Formoterol in a Subgroup of Patients from China with Symptomatic COPD at Risk of Exacerbations (FULFIL Trial)
- Source :
- COPD. 15(4)
- Publication Year :
- 2018
-
Abstract
- The FULFIL study evaluated once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100 µg/62.5 µg/25 µg versus twice-daily budesonide/formoterol (BUD/FOR) 400 µg/12 µg in patients with symptomatic COPD at risk of exacerbations. FULFIL demonstrated clinically meaningful and statistically significant improvements at Week 24 in trough forced expiratory volume in 1 second (FEV
- Subjects :
- Pulmonary and Respiratory Medicine
Budesonide
Male
medicine.medical_specialty
China
Quinuclidines
Health Status
Vital Capacity
Chlorobenzenes
Fluticasone propionate
03 medical and health sciences
chemistry.chemical_compound
Pulmonary Disease, Chronic Obstructive
0302 clinical medicine
Double-Blind Method
Internal medicine
Forced Expiratory Volume
medicine
Budesonide, Formoterol Fumarate Drug Combination
Humans
030212 general & internal medicine
Glucocorticoids
Benzyl Alcohols
Aged
COPD
business.industry
Middle Aged
medicine.disease
Bronchodilator Agents
Androstadienes
Drug Combinations
Treatment Outcome
030228 respiratory system
Budesonide/formoterol
UMECLIDINIUM/VILANTEROL
chemistry
Spirometry
Disease Progression
Quality of Life
Female
Formoterol
Vilanterol
Once daily
business
medicine.drug
Subjects
Details
- ISSN :
- 15412563
- Volume :
- 15
- Issue :
- 4
- Database :
- OpenAIRE
- Journal :
- COPD
- Accession number :
- edsair.doi.dedup.....d6391854a2e38247662fbe8b1247464f